Watch a free webinar featuring Dr. Wesley T. O’Neal, MD, FACC, Medical Director, Cardiovascular CT Cone Health Heart & Vascular Center of Greensboro NC
The unique diffusion tip of BD Nexiva Diffusics™ Closed IV Catheter System adds three laser-cut teardrop holes around the catheter tip. It can accommodate power injection up to 325 psi and meet high flow injection protocols.*
Nexiva Diffusics™ Catheter System is built on the Nexiva platform and is specifically designed to address the infusion challenges of contrast-enhanced CT.
*22 G up to 6.5 mL/sec
Unfortunately, many patients’ vasculature cannot accommodate 18- or even 20-gauge catheters, and using smaller gauge sizes can result in slower flow rates and reduced image quality.
While achieving appropriate flow rates is crucial to image quality, the high flow rates required for power injection during CT may also cause catheters to move or whip around in the vein which may lead to extravasation and could be costly.1,2
The Infusion Therapy Standards of Practice recommend placing the smallest-gauge catheter that will accommodate the prescribed therapy and patient need.3
The diffusion tip on Nexiva Diffusics™ Catheter System enables desired contrast media flow rates to be achieved using a smaller gauge catheter† without compromising image quality. This enables clinicians to perform CT scans that require high flow rates when a patient's vasculature cannot accommodate a large catheter (i.e., 18 or 20 gauge).‡,4
†22–24 gauge
‡Bench test results may not necessarily be indicative of clinical performance.
While flow rates of contrast media are important, the delivery force should also be considered. Nexiva Diffusics™ Catheter System’s diffusion tip reduces the force of contrast delivery by up to 48%,§ helping decrease the impact of contrast media on the vessel wall.
§Compared to a non-diffusion-tip catheter. Bench test results may not necessarily be indicative of clinical performance.
High flow rates required for power injection during CT may cause some catheters to move or whip around in the vein. Catheter motion may lead to extravasation, a complication caused by the catheter backing out of the vein.1
Extravasation may be painful for the patient, potentially resulting in tissue damage.3 The average potential liability for a moderate extravasation is $22k and up to $145k for a severe extravasation.2
Nexiva Diffusics™ Catheter System has been shown to reduce the forces that may cause catheter motion in the vein by up to 67%. This reduction in force stabilizes the catheter in the vein, and prevents the whipping, movement and backing out of the vein that may lead to extravasation.1
The videos below show catheter motion and extravasation of a non-diffusion tip catheter compared to the stability that Nexiva Diffusics™ Catheter System provides during power injection.
Note that, due to the force of the injection, the catheter tip will slowly move, backing out of the vein until the tip escapes the vein completely and contrast media enters the surrounding tissue.
Note the catheter stays in the vein, but the forces from the power injection create enough turbulence to cause the catheter tip to whip around within the vein. This creates significant motion, potentially irritating or damaging the vessel wall.
Note the contrast media flows throughout the vasculature, while the catheter remains still.
†Videos are from an animal study. Animal study results may not be indicative of clinical performance.
Nexiva Diffusics™ Catheter System is offered in two single port configurations: with and without BD MaxZero™ Needle-free Connectors.
BD-22672 (05/24)
Nexiva Diffusics™ Catheter System for cardiac CTs
The all-in-one closed IV catheter system leverages a fenestrated tip to accommodate power injection at high flow rates (e.g., 6.5 mL/sec for 22 G) and provides higher vascular attenuation for coronary CTA (CCTA) when compared with non-fenestrated catheters at the same flow rates.
Practice guidelines include using a fenestrated peripheral IV catheter (PIVC), ensuring the IV used is rated to administer flow rates required for coronary CTA (e.g., 5–7 mL/s).1
ensures high risk patients are appropriately triaged to cardiac catheterization1
offers rapid evaluation of the degree of coronary stenosis and atherosclerosis1
allows significant reduction in time-to-discharge1
Appropriate utilization and patient selection1
Requires high contrast media injection flow rates2
Extracting potential clinical and economic value for CCTA includes improving patient outcomes, lowering healthcare costs and preventing unnecessary diagnostic procedures.1
Watch a free webinar featuring Dr. Wesley T. O’Neal, MD, FACC, Medical Director, Cardiovascular CT Cone Health Heart & Vascular Center of Greensboro NC
Elevate infusion experiences for your patients
Fenestrated catheter in CCTA1,2
Nexiva Diffusics™ Catheter System is offered in two single port configurations: with and without BD MaxZero™ Needle-free Connectors.
Nexiva Diffusics™ Catheter System is built on the Nexiva™ platform. Nexiva™ has been shown to deliver higher clinician satisfaction, improved clinician safety and a reduction in overall complication rates versus non-integrated, open systems.1–3
The platform is backed by evidence in peer-reviewed journals from as early as 20094 to as recently as 2024.5
Nexiva™ Diffusics Closed IV Catheter System is also backed by peer-reviewed journals and infusion guidelines. Infusion Therapy Standards of Practice state to consider a fenestrated catheter for a contrast-based radiographic study and in coronary CTA.6 Nexiva Diffusics™ Catheter System is the only peripheral IV catheter with a diffusion catheter tip specifically designed for power injection.
Closed IV Catheter System | Comparative catheter | Data gathered | Year published | Study type | Journal | Authors |
Nexiva Diffusics™ | Smiths Jelco ProtectIV® Plus | Aortic enhancement levels, catheter placement success, complications, contrast volume, extravasation, image quality, infusion rate, maximum pressure | 2014 | RCT7 | American Journal of Roentgenology | Johnson PT, Christensen GM, Fishman EK. |
Nexiva™ | Various | Catheter failure, dislodgement, occlusion, phlebitis | 2024 | Systematic review/ meta analysis5 | Journal of Vascular Access | Gidaro A, Quici M, Giustivi D, et al. |
Nexiva™ | BD Insyte Autoguard™ | Dwell time, complications, dislodgement, occlusion, infiltration, phlebitis | 2023 | RCT8 | European Journal of Oncology Nursing | Gerceker GO,
Yildirim BG, Onal A, et al. |
Nexiva™ | B. Braun
Introcan
Safety® BD Insyte Autoguard™ | Catheter-associated bloodstream infection, clinician satisfaction, cost savings/utilization reduction, dwell time, dislodgement/leaking, infiltration/extravasation, local infection, insertion success, occlusion, phlebitis | 2022 | RCT1 | Journal of Hospital Medicine | Rickard CM,
Larsen E, Walker RM, et al. |
Nexiva™ | Smiths Jelco ProtectIV® Plus | Clinician satisfaction, dwell time, infection, infiltration, pain, phlebitis | 2019 | Prospective, quasi-experimental9 | Journal of Infusion Nursing | Penoyer D, Fowler S, Bennett M |
Nexiva™ | None | Blood exposure, dislodgement, kinking, leaking, phlebitis, restarts | 2017 | Observational10 | Journal of Vascular Access | deRosenroll A |
Nexiva™ | Medikit | Bending and kinking, blood exposure, cost savings/utilization reduction, dislodgement, dwell time, extravasation, insertion success, obstruction, phlebitis | 2014 | Quasi-randomized study11 | Journal of Vascular Access | Tamura N, Abe S, Hagimoto K, et al. |
Nexiva™ | B. Braun Vasocan® Safety | Catheter-related infection, cost savings/utilization reduction, dwell time, infiltration/extravasation, insertion success, occlusion, pain, painful hematoma, phlebitis | 2014 | RCT2 | Journal of Hospital Infection | González López J, Arribi Vilela A, Fernández Del, Palacio E, et al. |
Nexiva™ | B. Braun Introcan Safety® (non-winged) with StatLock | Clinician satisfaction, cost savings/utilization reduction, dislodgement, dwell time, infiltration, insertion success, leaking, phlebitis | 2010 | RCT3 | Journal of Infusion Nursing | Bausone-Gazda D, Lefaiver CA, Walters SA, et al. |
Nexiva™ | None | Clinician satisfaction, clotting, dislodgement, infiltration, leaking, restarts, securement | 2009 | Pre-and post-use survey4 | Journal of the Association of Vascular Access | McNeil E, Hines N, Phariss R |
Catalog no. | Color | Gauge | Catheter length (in) | Gravity flow rate (mL/min) | Maximum power
| Max power
|
383590 | Yellow | 24 | 0.75 | 21 | 325 | 3.00 mL/sec |
383591 | Blue | 22 | 1.00 | 45 | 325 | 6.50 mL/sec |
383592 | Pink | 20 | 1.00 | 68 | 325 | 10.00 mL/sec |
383593 | Pink | 20 | 1.25 | 64 | 325 | 10.00 mL/sec |
383594 | Green | 18 | 1.25 | 90 | 325 | 15.00 mL/sec |
*The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
Catalog no. | Color | Gauge | Catheter
| Catheter
| Catheter
| Extension
| Gravity
| Max power
| Packaging |
383595 | Yellow | 24 | .75 | 0.0210 (0.53) | 0.0280 (0.71) | 1.22 | 21 | 3.0 | 20/box 80/ case |
383596 | Blue | 22 | 1.00 | 0.0265 (0.67) | 0.0355 (0.90) | 1.22 | 45 | 6.5 | 20/box 80/ case |
383598 | Blue | 22 | 1.75 | 0.0265 (0.67) | 0.0355 (0.90) | 1.65 | 33 | 5.0 | 20/box 80/ case |
383597 | Pink | 20 | 1.00 | 0.0325 (0.83) | 0.0435 (1.10) | 1.65 | 68 | 10.0 | 20/box 80/ case |
383587 | Pink | 20 | 1.25 | 0.0325 (0.83) | 0.0435 (1.10) | 1.65 | 64 | 10.0 | 20/box 80/ case |
383599 | Pink | 20 | 1.75 | 0.0325 (0.83) | 0.0435 (1.10) | 1.65 | 53 | 8.5 | 20/box 80/ case |
383588 | Green | 18 | 1.25 | 0.0385 (0.98) | 0.0515 (1.31) | 1.65 | 90 | 15.0 | 20/box 80/ case |
393589 | Green | 18 | 1.75 | 0.0385 (0.98) | 0.0515 (1.31) | 1.65 | 84 | 11.0 | 20/box 80/ case |
*The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
Find our training resources to help improve your clinical practices as part of our goal of advancing the world of health.